Mario Falchi

Mario Falchi

Auto-generated profile, based on publicly available information

Mario Falchi

National AIDS Center, Istituto Superiore di Sanità, Rome, Italy

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2002 in Nature Medicine
Verified
Journal Article
Closed access
CSCecilia Sgadari
Cecilia Sgadari
GBGiovanni Barillari
Giovanni Barillari
ETElena Toschi
Elena Toschi
DCDavide Carlei
Davide Carlei
IBIlaria Bacigalupo
Ilaria Bacigalupo
Barbara EnsoliBarbara Ensoli
Barbara Ensoli

2 October 2000 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
SPStefania Parlato
Stefania Parlato
AGAnna Maria Giammarioli
Anna Maria Giammarioli
MLMariantonia Logozzi
Mariantonia Logozzi
FLFrancesco Lozupone
Francesco Lozupone
PMPaola Matarrese
Paola Matarrese
Stefano FaisStefano Fais
Stefano Fais
CD95 (APO‐1/Fas) is a member of the tumor necrosis factor receptor family, which can trigger apoptosis in a variety of cell types. However, little is known of the mechanisms underlying cell susceptibility to CD95‐mediated apoptosis. Here we show that human T cells that are susceptible to CD95‐mediated apoptosis, exhibit a constitutive polarized morphology, and that CD95 colocalizes with ezrin at the site of cellular polarization. In fact, CD95 co‐immunoprecipitates with ezrin exclusively in lymphoblastoid CD4+ T cells and primary long‐term activated T lymphocytes, which are prone to CD95‐mediated apoptosis, but not in short‐term activated T lymphocytes, which are refractory to the same stimuli, even expressing equal levels of CD95 on the cell membrane. Pre‐treatment with ezrin antisense oligonucleotides specifically protected from the CD95‐mediated apoptosis. Moreover, we show that the actin cytoskeleton integrity is essential for this function. These findings strongly suggest that the CD95 cell membrane polarization, through an ezrin‐mediated association with the actin cytoskeleton, is a key intracellular mechanism in rendering human T lymphocytes susceptible to the CD95‐mediated apoptosis.

2 May 2011 in Oncogene
Verified
Journal Article
Closed access
MMM Musumeci
M Musumeci
VCV Coppola
V Coppola
AAA Addario
A Addario
MPM Patrizii
M Patrizii
MMM Maugeri-Saccà
M Maugeri-Saccà
DBD Bonci
D Bonci

5 October 2018 in Cancers
Verified
Journal Article
Open access
PDF file
MLMariantonia Logozzi
Mariantonia Logozzi
DMDavide Mizzoni
Davide Mizzoni
DADaniela F. Angelini
Daniela F. Angelini
RRRossella Di Raimo
Rossella Di Raimo
MFMario Falchi
Mario Falchi
Stefano FaisStefano Fais
Stefano Fais
Exosomes are extracellular nanovesicles primarily involved in the pathogenesis of many diseases including cancer. This study was set out from recent evidence that extracellular acidity may increase the exosome release by cancer cells. However, this preliminary evidence did not provide solid information on whether the pH-dependent exosome over-release represents a common feature of all cancers. To the purpose of demonstrating that cancer acidity is a major determinant in inducing an increased exosome release by human cancer cells, we evaluated human tumor cell lines deriving from either colon, breast, prostate cancers, melanoma, or osteosarcoma. All cell lines were cultured in either the current 7.4 pH or the typical pH of cancer that is 6.5. The levels of released extracellular vesicles were measured by protein counts, nanoparticle tracking analysis (NTA), and nanoscale flow cytometry. The results showed that pH 6.5 induced a remarkable increase in exosome release, and buffering the medium significantly reduced the exosome release in all cancers. With these results, we provide, for the first time, evidence that tumor acidity and exosome levels represent common cancer phenotypes.

24 April 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SPStefania Parlato
Stefania Parlato
ANAdele De Ninno
Adele De Ninno
RMRosa Molfetta
Rosa Molfetta
ETElena Toschi
Elena Toschi
DSDebora Salerno
Debora Salerno
LGLucia Gabriele
Lucia Gabriele
Immunotherapy efficacy relies on the crosstalk within the tumor microenvironment between cancer and dendritic cells (DCs) resulting in the induction of a potent and effective antitumor response. DCs have the specific role of recognizing cancer cells, taking up tumor antigens (Ags) and then migrating to lymph nodes for Ag (cross)-presentation to naïve T cells. Interferon-α-conditioned DCs (IFN-DCs) exhibit marked phagocytic activity and the special ability of inducing Ag-specific T-cell response. Here, we have developed a novel microfluidic platform recreating tightly interconnected cancer and immune systems with specific 3D environmental properties, for tracking human DC behaviour toward tumor cells. By combining our microfluidic platform with advanced microscopy and a revised cell tracking analysis algorithm, it was possible to evaluate the guided efficient motion of IFN-DCs toward drug-treated cancer cells and the succeeding phagocytosis events. Overall, this platform allowed the dissection of IFN-DC-cancer cell interactions within 3D tumor spaces, with the discovery of major underlying factors such as CXCR4 involvement and underscored its potential as an innovative tool to assess the efficacy of immunotherapeutic approaches.

27 February 2019 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
LGLudovica Grassi
Ludovica Grassi
RARomina Alfonsi
Romina Alfonsi
FFFederica Francescangeli
Federica Francescangeli
MSMichele Signore
Michele Signore
MAMaria Laura De Angelis
Maria Laura De Angelis
DBDésirée Bonci
Désirée Bonci
The pressure towards innovation and creation of new model systems in regenerative medicine and cancer research has fostered the development of novel potential therapeutic applications. Kidney injuries provoke a high request of organ transplants making it the most demanding system in the field of regenerative medicine. Furthermore, renal cancer frequently threaten patients’ life and aggressive forms still remain difficult to treat. Ethical issues related to the use of embryonic stem cells, has fueled research on adult, patient-specific pluripotent stem cells as a model for discovery and therapeutic development, but to date, normal and cancerous renal experimental models are lacking. Several research groups are focusing on the development of organoid cultures. Since organoids mimic the original tissue architecture in vitro, they represent an excellent model for tissue engineering studies and cancer therapy testing. We established normal and tumor renal cell carcinoma organoids previously maintained in a heterogeneous multi-clone stem cell-like enriching medium. Starting from adult normal kidney specimens, we were able to isolate and propagate organoid 3D-structures composed of both differentiated and undifferentiated cells while expressing nephron specific markers. Furthermore, we were capable to establish organoids derived from cancer tissues although with a success rate inferior to that of their normal counterpart. Cancer cultures displayed epithelial and mesenchymal phenotype while retaining tumor specific markers. Of note, tumor organoids recapitulated neoplastic masses when orthotopically injected into immunocompromised mice. Our data suggest an innovative approach of long-term establishment of normal- and cancer-derived renal organoids obtained from cultures of fleshly dissociated adult tissues. Our results pave the way to organ replacement pioneering strategies as well as to new models for studying drug-induced nephrotoxicity and renal diseases. Along similar lines, deriving organoids from renal cancer patients opens unprecedented opportunities for generation of preclinical models aimed at improving therapeutic treatments.